Matt Cheung, PhD, RPh

Represented: Industry

Conflicts of Interest:

As of February 26, 2019

• Advanced Rx Consulting, LLC, Owner/Principal Consultant
• Aimmune Therapeutics Inc., Stock/Investments
• Amag Pharmaceuticals Inc., Stock/Investments
• Apple Inc., Stock/Investments
• Bristol-Myers Squibb Co., Stock/Investments
• Catalyst Pharmaceuticals Inc., Stock/Investments
• Clovis Oncology Inc., Stock/Investments
• General Electric Co., Stock/Investments
• Gerson Lehrman Group Inc., Consultant
• Heron Therapeutics Inc., Stock/Investments
• IBM Co., Stock/Investments
• Merck and Co. Inc., Stock/Investments
• Proctor and Gamble Co., Stock/Investments
• Red Hill Pharmaceuticals Ltd., Stock/Investments
• Sanofi Co., Stock/Investments
• Spectrum Pharmaceuticals Inc., Stock/Investments
• Stanford University, Scientific Advisory Committee, Member, Consultant
• University of the Pacific, Thomas J Long School of Pharmacy: Academic Institution, Employer
• Zimmer Biomet Holdings Inc., Stock/Investments

Cheung served as a member and Chair of the Advisory Panel on Rare Disease from August 2016 to August 2019.